Viking Therapeutics Inc (VKTX) Quarterly Institutional 13F Update (Q2 2026)

VKTX ranks #1373 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

VKTX is a top-conviction position for Diadema Partners LP — at 9.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in VKTX belongs to FMR LLC, but the position matters far more to Diadema Partners LP, who has 9.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

California State Teachers Retirement System has added to its VKTX position for two straight quarters, increasing it by $124.3M to reach $127.9M today.

Barclays PLC has trimmed its VKTX position for two straight quarters, cutting it by $16.1M while still holding $2.1M.

VKTX is up 1.9% today, and institutions have been net buyers of $459.4M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VKTX reported a net loss of $534.8M over the trailing twelve months.

• Not yet profitable — net loss of $534.8M over the trailing twelve months
• Net income declined year over year, from -$171.5M to -$534.8M
• Operating cash flow was negative, using $278.7M in cash
• Current ratio of 9.33x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range